Hims & Hers Health (HIMS) heads into its May 11 earnings report under closer watch as investors weigh margin concerns, rising competitive and legal pressures, and recent board changes that reshape the company’s governance profile.

Short term sentiment has cooled, with a 1 day share price return showing a decline of 4.58% and a 7 day share price return showing a decline of 5.59%. However, the 30 day share price return of 31.54% and multi year total shareholder returns suggest that longer term momentum has previously been much stronger.

If the recent volatility around Hims & Hers Health has you thinking about opportunities elsewhere in digital health, it could be worth scanning 35 healthcare AI stocks

With Hims & Hers Health trading near its US$26 analyst price target, yet carrying an implied intrinsic discount of about 57%, the key question is simple: is the stock mispriced, or is the market already baking in future growth?

Most Popular Narrative: 70.2% Undervalued

Hims & Hers Health’s most followed narrative suggests a fair value of $86.09 per share, compared with the recent $25.65 close. This indicates a very wide gap between what the market is pricing in and what this narrative expects.

Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock; it is described as quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States. It is executing a strategy similar to Amazon, Spotify, and Costco: deliver more value per dollar spent, reinvest scale advantages, and focus on customer-centric efficiency.

Want to see how this view arrives at that higher fair value? The narrative focuses on fast subscription growth, rising profitability, and ambitious long term margin targets.

Result: Fair Value of $86.09 (UNDERVALUED)

However, this bullish narrative could be tested if regulatory scrutiny around GLP 1 compounding tightens further, or if competition from larger healthcare and tech platforms intensifies.

Another Angle on Valuation

That user narrative leans heavily on discounted cash flows and long term margin assumptions. The current P/E of 46.2x tells a different story, with Hims & Hers Health priced more expensively than the US Healthcare industry at 22.1x and only slightly above its fair ratio of 45.3x. Against peers at 60.1x, the stock screens cheaper. However, the narrow gap to the fair ratio suggests less room for error if growth or margins disappoint. Which signal do you think the market pays more attention to next?

Next Steps

With sentiment clearly split between opportunity and risk, it makes sense to check the underlying data yourself and move quickly to form your own view using 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If Hims & Hers Health has caught your attention, do not stop here. Use the Simply Wall St screener to uncover other focused opportunities that could suit your approach.

• Target quality at a discount by reviewing the 51 high quality undervalued stocks that combine solid fundamentals with prices the market may be overlooking.
• Prioritise resilience by checking the 72 resilient stocks with low risk scores that aim for steadier returns and fewer unpleasant surprises.
• Get ahead of the crowd by scanning the screener containing 23 high quality undiscovered gems that have strong metrics but limited current attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.